Enclomiphene Citrate (Enclomiphene) – Comprehensive Research Overview (2026)

Enclomiphene citrate is the purified trans-isomer (E-isomer) of clomiphene citrate (Clomid). Unlike standard clomiphene, which is a 62:38 mixture of enclomiphene and zuclomiphene, enclomiphene isolates the active anti-estrogenic component. It is primarily researched as a selective estrogen receptor modulator (SERM) for the treatment of secondary (hypogonadotropic) hypogonadism in men. It stimulates natural testosterone production while preserving fertility and avoiding many of the drawbacks associated with exogenous testosterone replacement therapy (TRT).

→ View Enclomiphene (for laboratory research use only)

Chemical Structure and Properties

• Chemical Name: (E)-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine citrate
• Molecular Weight: ~406 Da (base)
• Form: Oral capsule or tablet (typically compounded)
• Bioavailability: High oral absorption with a shorter half-life than zuclomiphene

Mechanism of Action

Enclomiphene acts as a pure estrogen receptor antagonist at the hypothalamus and pituitary gland. By blocking estrogen negative feedback, it increases:

• Gonadotropin-releasing hormone (GnRH) pulses
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
• Endogenous testosterone production and spermatogenesis

This approach maintains an active hypothalamic-pituitary-gonadal (HPG) axis, unlike direct testosterone therapy.

Clinical Evidence and Research Findings

Enclomiphene has been evaluated in multiple Phase 2 and Phase 3 trials (including the ZA-304 and ZA-305 studies). Key outcomes include:

• Significant increases in total and free testosterone, often restoring levels to the normal physiologic range
• Preservation or improvement in sperm concentration and motility
• Better tolerability compared to clomiphene (lower rates of mood disturbances and visual side effects)

Despite promising results, development as Androxal was discontinued after FDA Complete Response Letters. It is currently used off-label through compounding pharmacies.

→ Interested in researching Enclomiphene? View Product Options

Benefits (Research & Clinical Observations)

• Supports natural testosterone production
• Preserves fertility and testicular function
• May improve energy, libido, mood, and body composition
• Lower risk of testicular atrophy and erythrocytosis compared to TRT

Typical Dosing Protocols (Off-Label / Compounded)

• Starting dose: 6.25 – 12.5 mg once daily (morning)
• Maintenance dose: 12.5 – 25 mg daily (some protocols use up to 50 mg)
• Many men achieve excellent results at 12.5 mg with minimal side effects
• Lab monitoring recommended every 4–8 weeks (testosterone, LH, FSH, estradiol, hematocrit, PSA)

Safety Profile and Side Effects

Enclomiphene is generally well-tolerated with a favorable profile compared to clomiphene.

Common side effects:

• Mild headache or nausea
• Temporary visual disturbances (less frequent than clomiphene)
• Possible mild estradiol elevation (monitor and manage if needed)

Advantages over TRT:

• No suppression of natural testosterone production
• No testicular atrophy
• Maintains fertility
• Lower risk of elevated hematocrit

Contraindications: Primary hypogonadism, history of prostate cancer, or known hypersensitivity.

Enclomiphene vs Clomiphene vs TRT – Quick Comparison

FAQ – Frequently Asked Questions

Is enclomiphene FDA approved? No. It is not approved as a finished drug product. It is available through compounding pharmacies under physician supervision for off-label use.

How does enclomiphene compare to Clomid? Enclomiphene is the purified active isomer and generally has fewer estrogenic side effects and better tolerability than the clomiphene mixture.

Can enclomiphene be used with TRT? It is sometimes used in combination protocols, but this should only be done under experienced medical supervision.

Does enclomiphene require PCT? No. Because it stimulates natural production rather than suppressing it, post-cycle therapy is typically not needed after discontinuation.

How long until results are seen? Most men notice improvements in energy, libido, and labs within 2–6 weeks, with peak effects around 6–8 weeks.

Summary

Enclomiphene citrate offers a targeted, fertility-friendly approach to raising endogenous testosterone in men with secondary hypogonadism. It bridges the gap between lifestyle interventions and full TRT, with a strong clinical data foundation and generally good tolerability. While not FDA-approved as a standalone medication, it remains a well-regarded option in hormone optimization and research settings when used under medical supervision.

For Laboratory Research Use View Enclomiphene →

Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.